MSB 2.70% 95.0¢ mesoblast limited

MSB to dispute FDA finding in Type A meeting, page-815

  1. 548 Posts.
    lightbulb Created with Sketch. 124
    Yep . We can guess , second guess , slice and dice all we want but we are guessing. But with agvhd not be approved it makes Remestemcell cheaper for Novartis to get in on the ground floor, maybe this was their reason for blocking????

    Anyway i am confident that Remestemcell will be approved for agvhd in this current process.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
95.0¢
Change
0.025(2.70%)
Mkt cap ! $1.084B
Open High Low Value Volume
94.0¢ 96.8¢ 93.5¢ $4.207M 4.417M

Buyers (Bids)

No. Vol. Price($)
3 42268 94.0¢
 

Sellers (Offers)

Price($) Vol. No.
95.0¢ 48002 3
View Market Depth
Last trade - 16.10pm 09/08/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.